» Articles » PMID: 33224240

Resveratrol Reduces Lipid Accumulation Through Upregulating the Expression of MicroRNAs Regulating Fatty Acid Bet Oxidation in Liver Cells: Evidence from and Studies

Overview
Publisher Brieflands
Specialty Pharmacology
Date 2020 Nov 23
PMID 33224240
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs have been shown to regulate lipogenesis in liver. The aim of the present study was to investigate whether the effects of resveratrol (RSV) on lipogenesis are associated with the changes in the expression of two miRNAs (miR-107 and miR-10b) that regulate lipogenic pathways. 30 wild type C57BL/6j male mice were randomly fed three diets: a standard chow diet (ND), a high fat diet (HFD, 60% fat) and the high fat diet supplemented with 0.4% RSV (HFD-RSV) for 16 weeks. HepG2 cells were treated with high glucose (33 mM) and RSV (20 µM) for 24 h. The expression of the genes and miRNAs were measured by real-time PCR. Triglyceride level was increased in the liver of mice and HepG2 cells. In both animal and experiments, triglyceride level was significantly decreased in groups treated with RSV. The expression of the miR-107 and miR-10b was significantly upregulated in the liver of HFD mice, whereas HFD-RSV group demonstrated a significant lower expression of both miRNAs compared to HFD group. In addition, RSV treatment significantly upregulated the expression of CPT-1a and PPARα genes in the liver of HFD mice. Moreover, treatment with RSV could reduce the expression of miR-107 and miR-10b and increase the expression of CPT-1a and PPARα in HG-treated HepG2 cells. These evidence, as a whole, suggest that RSV could exert its anti-lipogenic effect partially through alterations in the expression of miR-107 and miR-10b in liver cells.

Citing Articles

Tea leaf exosome-like nanoparticles (TELNs) improve oleic acid-induced lipid metabolism by regulating miRNAs in HepG-2 cells.

Lei X, Li H, Chen S, Li B, Xia H, Li J Bioresour Bioprocess. 2025; 12(1):9.

PMID: 39930300 PMC: 11810870. DOI: 10.1186/s40643-025-00844-1.


Bilirubin, a hepatoprotective agent that activates SIRT1, PGC-1α, and PPAR-α, while inhibiting NF-κB in rats with metabolic-associated fatty liver disease.

Taghizadeh M, Maleki M, Vakili O, Tavakoli R, Zarei P, Dehghanian A Sci Rep. 2024; 14(1):29244.

PMID: 39587213 PMC: 11589846. DOI: 10.1038/s41598-024-80119-5.

References
1.
Tiniakos D, Vos M, Brunt E . Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010; 5:145-71. DOI: 10.1146/annurev-pathol-121808-102132. View

2.
Gawlik K, Naskalski J, Fedak D, Pawlica-Gosiewska D, Grudzien U, Dumnicka P . Markers of Antioxidant Defense in Patients with Type 2 Diabetes. Oxid Med Cell Longev. 2015; 2016:2352361. PMC: 4657103. DOI: 10.1155/2016/2352361. View

3.
Jones C, Newbury S . Functions of microRNAs in Drosophila development. Biochem Soc Trans. 2010; 38(4):1137-43. DOI: 10.1042/BST0381137. View

4.
Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M . MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011; 474(7353):649-53. DOI: 10.1038/nature10112. View

5.
Portius D, Sobolewski C, Foti M . MicroRNAs-Dependent Regulation of PPARs in Metabolic Diseases and Cancers. PPAR Res. 2017; 2017:7058424. PMC: 5266863. DOI: 10.1155/2017/7058424. View